Terms: = Colorectal cancer AND TET2, Q6N021, MGC125715, KIAA1546, FLJ20032, ENSG00000168769, 54790
24 results:
1. Nuclear localization of tet2 requires β-catenin activation and correlates with favourable prognosis in colorectal cancer.
Li C; He J; Meng F; Wang F; Sun H; Zhang H; Dong L; Zhang M; Xu Q; Liang L; Li Y; Yang T; He M; Wang T; Lin J; Sun J; Huang Q; Guo L; Zhang X; Mai S; Zheng H
Cell Death Dis; 2023 Aug; 14(8):552. PubMed ID: 37620362
[TBL] [Abstract] [Full Text] [Related]
2. Modulation of AMPK/ tet2/ 5-hmC axis in response to metabolic alterations as a novel pathway for obesity-related colorectal cancer development.
Kon T; Sasaki Y; Abe Y; Onozato Y; Yagi M; Mizumoto N; Sakai T; Umehara M; Ito M; Nakamura S; Goto H; Ueno Y
Sci Rep; 2023 Feb; 13(1):2858. PubMed ID: 36806702
[TBL] [Abstract] [Full Text] [Related]
3. tet2-BCLAF1 transcription repression complex epigenetically regulates the expression of colorectal cancer gene Ascl2 via methylation of its promoter.
Shang Y; Jiang T; Ran L; Hu W; Wu Y; Ye J; Peng Z; Chen L; Wang R
J Biol Chem; 2022 Jul; 298(7):102095. PubMed ID: 35660018
[TBL] [Abstract] [Full Text] [Related]
4. The Effect and Potential Mechanism of microRNA-124 on the Biological Behavior of Colon cancer Cells.
Zhou G
Ann Clin Lab Sci; 2021 Sep; 51(5):646-653. PubMed ID: 34686506
[TBL] [Abstract] [Full Text] [Related]
5. The transition from primary colorectal cancer to isolated peritoneal malignancy is associated with an increased tumour mutational burden.
Hallam S; Stockton J; Bryer C; Whalley C; Pestinger V; Youssef H; Beggs AD
Sci Rep; 2020 Nov; 10(1):18900. PubMed ID: 33144643
[TBL] [Abstract] [Full Text] [Related]
6. Demethylation of the RB1 promoter concomitant with reactivation of tet2 and TET3 impairs gastric carcinogenesis in K19-Wnt1/C2mE transgenic mice.
Cao D; Jia Z; Wu Y; Su T; Zhao D; Wu M; Tsukamoto T; Oshima M; Jiang J; Cao X
Life Sci; 2020 Dec; 263():118580. PubMed ID: 33058920
[TBL] [Abstract] [Full Text] [Related]
7. Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic cancer Types.
Topham JT; Titmuss E; Pleasance ED; Williamson LM; Karasinska JM; Culibrk L; Lee MKC; Mendis S; Denroche RE; Jang GH; Kalloger SE; Wong HL; Moore RA; Mungall AJ; O'Kane GM; Knox JJ; Gallinger S; Loree JM; Mager DL; Laskin J; Marra MA; Jones SJM; Schaeffer DF; Renouf DJ
Mol Cancer Ther; 2020 Sep; 19(9):1889-1897. PubMed ID: 32518206
[TBL] [Abstract] [Full Text] [Related]
8. Somatic mutation and loss of expression of a candidate tumor suppressor gene TET3 in gastric and colorectal cancers.
Mo HY; An CH; Choi EJ; Yoo NJ; Lee SH
Pathol Res Pract; 2020 Mar; 216(3):152759. PubMed ID: 31859118
[TBL] [Abstract] [Full Text] [Related]
9. DNA methylation instability by BRAF-mediated TET silencing and lifestyle-exposure divides colon cancer pathways.
Noreen F; Küng T; Tornillo L; Parker H; Silva M; Weis S; Marra G; Rad R; Truninger K; Schär P
Clin Epigenetics; 2019 Dec; 11(1):196. PubMed ID: 31842975
[TBL] [Abstract] [Full Text] [Related]
10. STAT5 and tet2 Cooperate to Regulate FOXP3-TSDR Demethylation in CD4
Ma H; Gao W; Sun X; Wang W
J Immunol Res; 2018; 2018():6985031. PubMed ID: 30013992
[TBL] [Abstract] [Full Text] [Related]
11. Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions-benign adenomas and inflammatory bowel disease.
Dziaman T; Gackowski D; Guz J; Linowiecka K; Bodnar M; Starczak M; Zarakowska E; Modrzejewska M; Szpila A; Szpotan J; Gawronski M; Labejszo A; Liebert A; Banaszkiewicz Z; Klopocka M; Foksinski M; Marszalek A; Olinski R
Clin Epigenetics; 2018; 10():72. PubMed ID: 29875879
[TBL] [Abstract] [Full Text] [Related]
12. Germline mutations in candidate predisposition genes in individuals with cutaneous melanoma and at least two independent additional primary cancers.
Pritchard AL; Johansson PA; Nathan V; Howlie M; Symmons J; Palmer JM; Hayward NK
PLoS One; 2018; 13(4):e0194098. PubMed ID: 29641532
[TBL] [Abstract] [Full Text] [Related]
13. The co-regulatory networks of tumor suppressor genes, oncogenes, and miRNAs in colorectal cancer.
Slattery ML; Herrick JS; Mullany LE; Samowitz WS; Sevens JR; Sakoda L; Wolff RK
Genes Chromosomes Cancer; 2017 Nov; 56(11):769-787. PubMed ID: 28675510
[TBL] [Abstract] [Full Text] [Related]
14. Targeted sequencing-based analyses of candidate gene variants in ulcerative colitis-associated colorectal neoplasia.
Chakrabarty S; Varghese VK; Sahu P; Jayaram P; Shivakumar BM; Pai CG; Satyamoorthy K
Br J Cancer; 2017 Jun; 117(1):136-143. PubMed ID: 28524162
[TBL] [Abstract] [Full Text] [Related]
15. Genetic Variants in Epigenetic Pathways and Risks of Multiple cancers in the GAME-ON Consortium.
Toth R; Scherer D; Kelemen LE; Risch A; Hazra A; Balavarca Y; Issa JJ; Moreno V; Eeles RA; Ogino S; Wu X; Ye Y; Hung RJ; Goode EL; Ulrich CM;
Cancer Epidemiol Biomarkers Prev; 2017 Jun; 26(6):816-825. PubMed ID: 28115406
[No Abstract] [Full Text] [Related]
16. Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers.
Li L; Li C; Mao H; Du Z; Chan WY; Murray P; Luo B; Chan AT; Mok TS; Chan FK; Ambinder RF; Tao Q
Sci Rep; 2016 May; 6():26591. PubMed ID: 27225590
[TBL] [Abstract] [Full Text] [Related]
17. Loss of nuclear localization of tet2 in colorectal cancer.
Huang Y; Wang G; Liang Z; Yang Y; Cui L; Liu CY
Clin Epigenetics; 2016; 8():9. PubMed ID: 26816554
[TBL] [Abstract] [Full Text] [Related]
18. 5-hydroxymethylcytosine marks promoters in colon that resist DNA hypermethylation in cancer.
Uribe-Lewis S; Stark R; Carroll T; Dunning MJ; Bachman M; Ito Y; Stojic L; Halim S; Vowler SL; Lynch AG; Delatte B; de Bony EJ; Colin L; Defrance M; Krueger F; Silva AL; Ten Hoopen R; Ibrahim AE; Fuks F; Murrell A
Genome Biol; 2015 Apr; 16(1):69. PubMed ID: 25853800
[TBL] [Abstract] [Full Text] [Related]
19. Clinical significance of DNA methylation mRNA levels of TET family members in colorectal cancer.
Rawłuszko-Wieczorek AA; Siera A; Horbacka K; Horst N; Krokowicz P; Jagodziński PP
J Cancer Res Clin Oncol; 2015 Aug; 141(8):1379-92. PubMed ID: 25557833
[TBL] [Abstract] [Full Text] [Related]
20. TET1 is a tumour suppressor that inhibits colon cancer growth by derepressing inhibitors of the WNT pathway.
Neri F; Dettori D; Incarnato D; Krepelova A; Rapelli S; Maldotti M; Parlato C; Paliogiannis P; Oliviero S
Oncogene; 2015 Aug; 34(32):4168-76. PubMed ID: 25362856
[TBL] [Abstract] [Full Text] [Related]
[Next]
